Author

N. E. Berlow

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. D. Woods· 1 shared B. Royer-Pokora· 1 shared C. A. Keller· 1 shared C. A. Ricker· 1 shared C. Keller· 1 shared G. A. Li· 1 shared G. Srivivasa· 1 shared H.-I. H. Chen· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. D. Woods

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Bromodomain 4 inhibition leads to MYCN downregulation in Wilms' tumor cells

A. D. Woods, C. Keller, N. E. Berlow, J. E. Michalek, B. Royer-Pokora, R. Purohit, K. E. Tranbarger Freier, M. Lathara, K. Matlock, G. Srivivasa, R. Veselska

This study shows that BRD4 inhibition reduces MYCN levels and suppresses proliferation in Wilms tumor cells, suggesting AZD5153 as a potential therapeutic agent.

bioRxiv · Jan 4, 2021 · PreprintCancer Biology

MEK1/2 in Rhabdomyosarcoma

K. A. Crawford, M. M. Cleary, C. A. Ricker, M. N. Svalina, J. F. Shern, H.-I. H. Chen, N. E. Berlow, C. A. Keller, G. A. Li

This study evaluates the combination of MEK inhibitor cobimetinib and chemotherapy in rhabdomyosarcoma, finding no significant additive or synergistic effects and potential antagonistic effects on chemotherapy efficacy.

bioRxiv · May 28, 2019 · PreprintCancer Biology